febrile

Febrile #108 – StAR: MDR GN

108 Cover Art OPT

Summary

This StAR episode features the CID State-of-the-Art Review on infections caused by multidrug-resistant Gram-negative organisms. Our guest stars this episode are Drs. Arsheena Yassin and Mariya Huralska from Robert Wood Johnson University Hospital

Table of Contents

Credits

Host: Sara Dong

Guests: Arsheena Yassin, Mariya Huralska

Content is based on the CID article featured in this episode although with additional writing by Sara Dong

Edited and Produced by Sara Dong with support from the Infectious Diseases Society of America (IDSA)

Our Guests

Arsheena Yassin, PharmD, BCIDP, AAHIVP

Dr. Arsheena Yassin is an Infectious Disease Pharmacist at Robert Wood Johnson University Hospital in New Jersey. She completed her pharmacy residency in Infectious Diseases at Mount Sinai Hospital and Touro College of Pharmacy in New York.

Mariya Huralska, MD

I was born in Ukraine and made my grand entrance into NYC at the ripe old age of 8. After graduating from medical school at Saba University Medical School in the Netherlands Antilles, I completed Internal Medicine Residency at Detroit Medical Center Huron Valley Sinai Hospital. It was during this time that I realized my passion for infectious diseases, and now I’m in my second year of ID Fellowship at Robert Wood Johnson University Hospital. When I’m not fighting off germs, you can find me unwinding with some guilty pleasure reality TV and soaking up quality time with my friends and family.

Culture

Arsheena enjoys being outside and listening to music (all types depending on mood!)

Mariya shared the Ukranian comedy/satire series “Servant of the People”, starring President Zelenskyy

Consult Notes

Goal

Listeners will be able to discuss a framework for identifying patients at risk for multidrug-resistant Gram-negative organism infections

Learning Objectives

After listening to this episode, listeners will be able to:

  • Describe the core initial evaluation for management of infections caused by multidrug-resistant Gram negative organisms, with an emphasis on assessing patient history for MDR-GN risk factors
  • Discuss how to choose an appropriate empiric antibiotic regimen for a critically ill patient with risk factors for MDR-GN infection
  • Discuss the importance of multidisciplinary teams for managing patients with MDR-GN infections while inpatient as well as ensuring safe transition to the outpatient setting

Disclosures

Febrile podcast reports no relevant financial disclosures

Potential conflicts of interest are noted in the CID article as well as reproduced below:

A. Y. and M. H. report no potential conflicts of interest

Other conflicts of interest from article authors who were not featured on the podcast:

J. M. P. reports a grant from Merck and consulting fees from Merck, Shionogi, AbbVie, Entasis, Qpex, Melinta, La Jolla, and VenatoRx.

R. G. S. reports consulting fees from AbbVie and MoInIycke and serving as a board member of the Surgical Infection Society Foundation.

K. S. K. reports a grant from the National Institutes of Health (NIH) and Agency for Healthcare Research and Quality; consulting fees from Shionogi, Allecra, Spero, Qpex, Merck, GSK, VenatoRx, MicuRx, and Entasis; participation on advisory boards for VenatoRx, Entasis, the Division of Microbiology and Infectious Diseases of the NIH, and Meji Seika Pharma; and having stock in Merck.

Citation

Yassin, A., Huralska, M., Dong, S. “#108: StAR: MDR GN”. Febrile: A Cultured Podcast. https://share.descript.com/view/IBXwemVFyrQ

Transcript

Scroll to Top